Cullinan Therapeutics Inc (NASDAQ: CGEM) on Tuesday, plunged -2.81% from the previous trading day, before settling in for the closing price of $13.17. Within the past 52 weeks, CGEM’s price has moved between $7.64 and $30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. The company achieved an average annual earnings per share of 17.78%. With a float of $37.06 million, this company’s outstanding shares have now reached $58.14 million.
Let’s look at the performance matrix of the company that is accounted for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cullinan Therapeutics Inc is 36.36%, while institutional ownership is 77.32%. The most recent insider transaction that took place on Nov 05 ’24, was worth 125,120. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $15.64, taking the stock ownership to the 107,942 shares. Before that another transaction happened on Sep 05 ’24, when Company’s Chief Scientific Officer sold 8,000 for $18.09, making the entire transaction worth $144,720. This insider now owns 115,942 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.54 earnings per share (EPS) for the period topping the consensus outlook (set at -0.98) by 0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.78% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Cullinan Therapeutics Inc (CGEM) is currently performing well based on its current performance indicators. A quick ratio of 24.46 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.12 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 0.54 million, a negative change from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 58.53%. Additionally, its Average True Range was 0.90.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 8.47%, which indicates a significant decrease from 17.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.06% in the past 14 days, which was lower than the 59.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.50, while its 200-day Moving Average is $18.23. Nevertheless, the first resistance level for the watch stands at $13.40 in the near term. At $14.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.37. If the price goes on to break the first support level at $12.42, it is likely to go to the next support level at $12.05. Assuming the price breaks the second support level, the third support level stands at $11.45.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
Market capitalization of the company is 745.31 million based on 58,228K outstanding shares. Right now, sales total 0 K and income totals -153,160 K. The company made 0 K in profit during its latest quarter, and -40,560 K in sales during its previous quarter.
